Cytogenetic Studies in Acute Leukemia and Multiple Myeloma | NCT00048958

NCT00048958

Secondary IDs

ID	Type	Description	Link
NCI-2009-00494	Registry Identifier	CTRP (Clinical Trials Reporting Program)
CDR0000256897	Registry Identifier	PDQ (Physician Data Query)
3U24CA114725-09S1	U.S. NIH Grant/Contract		View source

Status Module

Sponsor/Collaborators Module

Name	Class
National Cancer Institute (NCI)	NIH

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
No treatment		Samples as defined per the protocol for previously untreated patients with AML, ALL, MDS or MM will be submitted for analysis and within one month patients are required to register onto a CALGB treatment study.	Genetic: cytogenetic analysis

Name	Type	Description	Arm Group Labels	Other Names
cytogenetic analysis	Genetic		No treatment

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Determine the incidence of specific less common primary as well as common secondary chromosome abnormalities in adult AML, ALL, MDS and MM		Up to 10 years
Correlate specific (normal or various primary and secondary chromosomal abnormalities) with clinical and laboratory parameters		Up to 10 years
Correlate specific karyotype groups with response rates, response duration, survival and cure in patients treated with various induction and post-induction regimens		Up to 10 years
Correlate specific karyotype groups with selected molecular abnormalities as studied in CALGB leukemia protocols		Up to 10 years
To correlate specific karyotype groups with multidrug resistance data		Up to 10 years
To correlate specific karyotype groups with epidemiologic data (toxic exposure and family history)		Up to 10 years
To determine karyotype changes at relapse and the influence of the type of change (or no change) in karyotype at relapse on subsequent clinical course		up to 10 yeras
To identify new chromosome abnormalities important in leukemogenesis		Up to 10 years

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Clara Bloomfield, MD	James Cancer Hospital and Solove Research Institute	Study Chair

Facility	Status	City	State	ZIP	Country	Contacts
Rebecca and John Moores UCSD Cancer Center		La Jolla	California	92093-0658	United States
Camino Medical Group - Treatment Center

References Module

Citations

PubMed Identifier	Type	Citation
16110030	Background	Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20;23(24):5705-17. doi: 10.1200/JCO.2005.15.610.
	Background	Mrozek K, Carroll AJ, Maharry K, et al.: Central review of cytogenetics is essential for cooperative group clinical and correlative studies of acute leukemia: The Cancer and Leukemia Group B (CALGB) 8461 experience. [Abstract] Blood 104 (11): A-1081, 2004.
14976037

IPD Sharing Statement Module

No data available